Table 1 Patient characteristics.
Pt | Age | Sex | Diagnosis | Treatment | Local side effects | Systemic side effects | Pre anti-N IgG OD | Pre anti-S IgG EC50 | Post anti-S IgG EC50 | Post neut. Ab ID50 | Post CD4+ | Post CD8+ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
01 | 55 | F | ET | Peg-IFN | None | None | 0.317 | <25 | 25 | 95 | + | + |
02 | 62 | M | ET | Peg-IFN | None | Fatigue | 0.204 | <25 | 31 | 243 | + | + |
03 | 47 | M | MF | Surveillance | Localised inflammation | None | 0.228 | <25 | <25 | 133 | NA | NA |
04 | 50 | F | PV | Surveillance/ Venesection | None | None | 0.243 | <25 | <25 | <25 | + | + |
05 | 63 | F | ET | Surveillance | Localised inflammation | None | 0.207 | <25 | 25 | 156 | − | − |
06 | 37 | M | PV | HC | None | Headache, Fatigue | 0.339 | <25 | 810 | 2163 | + | − |
07 | 43 | F | MF | Ruxolitinib | None | Dizziness | 0.256 | <25 | <25 | <25 | + | − |
08 | 63 | F | MF | Ruxolitinib | Localised inflammation | Fatigue | 0.900 | 25 | 5788 | 3999 | + | − |
09 | 40 | F | ET | Surveillance | None | Diarrhoea | 0.326 | <25 | 457 | 689 | − | − |
10 | 72 | M | MF | Surveillance | Localised inflammation | None | 1.772 | 41 | 9618 | 13709 | + | + |
11 | 64 | F | MF | Surveillance | Localised inflammation | None | 0.266 | 25 | 8783 | 15417 | + | + |
12 | 64 | F | ET | HC | Localised inflammation | Fatigue | 0.194 | <25 | 25 | 127 | − | − |
13 | 36 | M | MF | Ruxolitinib IMG-7289 | None | None | 0.187 | <25 | 25 | 381 | + | + |
14 | 59 | F | MF | Ruxolitinib | None | None | 0.216 | <25 | <25 | <25 | + | − |
15 | 70 | F | PV | Ruxolitinib | Localised inflammation | Fatigue | 0.194 | <25 | 25 | 98 | − | − |
16 | 59 | M | ET | Peg-IFN | Localised inflammation | Flu-like illness | 0.242 | <25 | 358 | 1151 | + | − |
17 | 58 | M | MF | Ruxolitinib | None | Flu-like illness | 1.504 | 25 | 6460 | 23823 | + | − |
18 | 58 | F | ET | HC | Localised inflammation | Nausea | 0.198 | <25 | 120 | 533 | + | − |
19 | 40 | F | ET | Peg-IFN | Localised inflammation | None | 0.370 | <25 | 25 | 366 | + | + |
20 | 60 | F | MF | Hydroxy-carbamide | Localised inflammation | None | 1.739 | <25 | 457 | 1977 | + | − |
21 | 56 | F | PV | Surveillance/Venesection | Localised inflammation | None | 0.099 | NA | < 25 | 213 | − | − |
